Man verliest zicht aan beide ogen na Ozempic-gebruik en klaagt fabrikant aan #Ozempic #Gezichtsverlies #Diabetes #NovoNordisk #Rechtszaak
@newsmonkey.bsky.social
@newsmonkey.bsky.socialMan verliest zicht aan beide ogen na Ozempic-gebruik en klaagt fabrikant aan #Ozempic #Gezichtsverlies #Diabetes #NovoNordisk #Rechtszaak
@nordic.skyen.live🇩🇰 Diabetespatienter oplever højere blodsukker midt på ugen
@replaye.bsky.socialMan claims he went blind after taking Ozempic, shares warning for other users
replaye.com/man-claims-h...
@astrolabex.bsky.socialNovo Nordisk faced a brutal ~56-75% stock drop from its 2024 peak over 18 months. This followed the surprise exit of CEO Lars Fruergaard Jørgensen and the appointment of Maziar 'Mike' Dostdar. Weeks into his tenure, Dostdar announced ~9,000 layoffs, a historic number for Denmark. #NovoNordisk
@nile11.bsky.socialU.S. Obesity Rate Drops as GLP-1 Drug Prices Plunge
..................
https://nile1.com/u-s-obesity-rate-drops-as-glp-1-drug-prices-plunge/
..................
#eliLilly #exenatide #fda #genericDrugs #gilaMonster #glp-1 #johnEng #novoNordisk #obesityRate #semaglutide #tirzepatide #type2Diabetes #weg
@notexx.deđź’Š Abnehmpillen beflĂĽgeln Pharmabranche
Seit September gibt es Wegovy von Novo Nordisk in Deutschland als Tablette. Der Wirkstoff Semaglutid bleibt gleich, die Kosten liegen bei 170 bis 280 Euro monatlich.
@financiernews.bsky.socialNotable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Centene in focus
@businessam-fr.bsky.socialNovo Nordisk conclut un accord de licence de plusieurs milliards pour des injections à action prolongée contre l’obésité et le diabète #NovoNordisk #Obésité #Diabète #Santé #Médecine
@businessam.bsky.socialNovo Nordisk sluit miljardenlicentie voor langwerkende obesitas- en diabetesinjecties #NovoNordisk #Diabetes #Obesitas #Farmacie #Innovatie
@quartzmedia.bsky.socialICYMI: Novo Nordisk bets $1.3B on obesity shots you'd only take monthly #NovoNordisk #ObesityTreatment
@quartzmedia.bsky.socialNovo Nordisk bets $1.3B on obesity shots you'd only take monthly #NovoNordisk #ObesityTreatment
@newsen.bsky.socialNanexa and Novo Join Forces with EUR 1.165 Billion Licensing Agreement #Sweden #NovoNordisk #Uppsala #Nanexa #PharmaShell
@theworldeye.bsky.socialBREAKING: Novo Nordisk faces rising investor pressure as markets question the long-term growth pipeline beyond its dominant obesity treatments.
@jlsweekly.bsky.socialJLSW Daily Brief #99: Novo Nordisk's 2030 plan (5+ blockbusters, oral GLP-1) drew a cool reception; shares fell 7%+ on Sep 21. Amgen's dazodalibep met its Ph3 primary endpoint in Sjögren's.
#GLP1 #NovoNordisk #LifeSciencesJapan
https://jlsweekly.substack.com/p/jlsw-daily-brief-09920260923
@newsmason.bsky.social#trends today for 'donatella versace' 'hall of fame' & 'novo nordisk'
Click/Tap below:
www.newsmason.com?query=%22don...
www.newsmason.com?query=%22hal...
@richiewhites.bsky.socialWhy did Novo Nordisk fall more than 5%?
Shares dropped after the company’s new 2030 strategy failed to meet investor expectations.
#NovoNordisk #PharmaStocks #Healthcare #EuropeanStocks #NVO #MarketNews
@premarketprice.bsky.social$NVO drops 6% on 10.5x volume as its 2030 growth strategy disappoints investors, overshadowing positive CagriSema trial data. #NovoNordisk #Obesity
View Analysis: https://premarketprice.com/analysis/NVO
@kautious.comNovo Nordisk fell ~5%-7% after Capital Markets Day: 2026-30 growth “in line with peers” disappointed. Targets: >5 potential blockbusters by 2030, >DKK150bn pipeline sales by 2035; 4,000 more departures. Watch Lilly, semaglutide LOE and CagriSema (12.4% vs 9.1%). #NovoNordisk #obesity
@quartzmedia.bsky.socialICYMI: A century of medical breakthroughs compressed into a decade? #NovoNordisk #Anthropic
@4040rec.bsky.social